We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) Antibodies|
|Epitope||Extracellular Domain Alternatives|
|Conjugate||This VEGFR2 antibody is conjugated to Biotin Alternatives|
Enzyme Immunoassay (EIA), Functional Studies (Func), Immunoprecipitation (IP), Western Blotting (WB)
|3 references available|
|Supplier||Log in to see|
Product Details anti-VEGFR2 AntibodyTarget Details VEGFR2 Application Details Handling References for anti-VEGFR2 antibody (ABIN155183) Images
|Specificity||The antibody will detect native and recombinant VEGFR-2/KDR.|
|Purification||Antigenaffinity chromatography with immobilised recombinant soluble VEGFR-2/KDR|
|Immunogen||Highly pure recombinant human soluble extracellular domain of KDR (110 kDa)|
Target Details VEGFR2Product Details anti-VEGFR2 Antibody Application Details Handling References for anti-VEGFR2 antibody (ABIN155183) Images back to top
|Alternative Name||CD309 / VEGFR-2 / Flk-1 (KDR Antibody Abstract)|
|Background||VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2|
|Research Area||Cytokines, Receptors|
|Pathways||RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling|
Application DetailsProduct Details anti-VEGFR2 Antibody Target Details VEGFR2 Handling References for anti-VEGFR2 antibody (ABIN155183) Images back to top
ELISA: 5-15 μg/mL. Western blot. Immunoprecipitation. Neutralizing experiments.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-VEGFR2 Antibody Target Details VEGFR2 Application Details References for anti-VEGFR2 antibody (ABIN155183) Images back to top
|Reconstitution||Reconstitute in sterile water to a concentration of 0.1 mg/mL.|
|Buffer||PBS pH 7.4 w/o preservative and stabilizer|
|Precaution of Use||Do Not Add Sodium Azide|
|Handling Advice||Dilute only prior to immediate use. Avoid cycles of freezing and thawing.|
|Storage||4 °C/-20 °C|
|Storage Comment||Store vial at 2-8 °C prior to restoration. For extended storage reconstitute product with 50% glycerol instead of water and then aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This antibody is stable for one month at 2-8 °C as an undiluted liquid.|
References for anti-VEGFR2 antibody (ABIN155183)Product Details anti-VEGFR2 Antibody Target Details VEGFR2 Application Details Handling Images back to top
Morbidelli, Birkenhaeger, Roeckl, Granger, Kaerst, Weich, Ziche: "Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers." in: Angiogenesis, Vol. 1, Issue 1, pp. 117-30, 2003
Simon, Röckl, Hornig, Gröne, Theis, Weich, Fuchs, Yayon, Gröne: "Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites." in: Journal of the American Society of Nephrology : JASN, Vol. 9, Issue 6, pp. 1032-44, 1998
Clauss, Weich, Breier, Knies, Röckl, Waltenberger, Risau: "The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis." in: The Journal of biological chemistry, Vol. 271, Issue 30, pp. 17629-34, 1996